Over 55 million people globally live with Alzheimer’s disease(AD)or related dementias(ADRD)and the number is expected to double every twenty years.Unt i l recent l y,onl y symptomatic treatments were available to pat...Over 55 million people globally live with Alzheimer’s disease(AD)or related dementias(ADRD)and the number is expected to double every twenty years.Unt i l recent l y,onl y symptomatic treatments were available to patients with AD,including acetylcholine esterase inhibitors,of which the last one,galantamine,was approved by the US Food and Drug Administration(FDA)in 2001.展开更多
Synucleinopathies are neurodegenerative diseases char-acterized by accumulation of misfoldedα-synuclein(α-syn)inclusions in neuronal and/or glial cells.Despite differences in the underlying pathophysiology,synucle-i...Synucleinopathies are neurodegenerative diseases char-acterized by accumulation of misfoldedα-synuclein(α-syn)inclusions in neuronal and/or glial cells.Despite differences in the underlying pathophysiology,synucle-inopathies often are misdiagnosed,especially in early stages,due to the overlapping clinical symptoms[1].展开更多
基金supported by NIH grants RF1NS126406 and R21NS130326by a generous gift from the Binder Foundation (to GB)
文摘Over 55 million people globally live with Alzheimer’s disease(AD)or related dementias(ADRD)and the number is expected to double every twenty years.Unt i l recent l y,onl y symptomatic treatments were available to patients with AD,including acetylcholine esterase inhibitors,of which the last one,galantamine,was approved by the US Food and Drug Administration(FDA)in 2001.
基金supported by grants from the MSA Coalition 2017-10-007(GB)California Department of Public Health 18-10926(GB)+5 种基金The Alzheimer’s Association,The Michael J.Fox Foundation,Weston Brain Institute,and Alzheimer’s Research UK Biomarkers Across Neurodegenerative Diseases(BAND 3)17990(GB)CurePSP 665-2019-07(GB)The Michael J.Fox Foundation 18303(GB)The National Ataxia Foundation 20201551(GB and BLF),Cure Sanfilippo Foundation 20215318(GB)NIH/NIEHS ES10544(BR)generous gifts from the Karen Toffler Charitable Trust and the Binder Foundation。
文摘Synucleinopathies are neurodegenerative diseases char-acterized by accumulation of misfoldedα-synuclein(α-syn)inclusions in neuronal and/or glial cells.Despite differences in the underlying pathophysiology,synucle-inopathies often are misdiagnosed,especially in early stages,due to the overlapping clinical symptoms[1].
